During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several presentations highlighted novel strategies that move beyond traditional antibody-drug conjugate payloads and targets.
Convalife Pharmaceuticals Co. Ltd. has presented data for their bispecific antibody CVL-006, which targets both PD-1 and VEGF-A. CVL-006 blocks both the PD-1-driven immune pathway plus VEGF-A-driven angiogenesis, thus conferring a dual mechanism for superior antitumoral activity.
Cancer of the uterus is the most common gynecological malignancy in the U.S., with over 60,000 diagnoses per year, where incidence and mortality have increased through the years. About 30%-40% of patients with high-grade disease harbor mutations in the PPP2R1A gene, which encodes the primary subunit of protein phosphatase 2A, with hotspots being P179R and S256F.
At this year’s AACR-NCI-EORTC conference, several presentations brought to light new ways to tackle the treatment of genomically unstable cancers. Genomically unstable cancers can be treated by exploiting their repair dependencies, inducing catastrophic DNA damage, or harnessing immune responses to instability.
Preclinical results were recently presented from studies conducted by Fulcrum Therapeutics Inc. evaluating FTX-6274, a novel, orally bioavailable embryonic ectoderm development (EED) inhibitor that targets the PRC2 complex, in models of castration-resistant prostate cancer.
Mutant KRAS is a well-known oncogenic driver and has remained undruggable for many decades. The development of pan-KRAS inhibitors that target a broad range of mutations is a promising approach to cancer treatment.
At the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 in Boston, Bridgebio Oncology Therapeutics Inc. (BBOT) presented data on BBO-11818, a potent and selective KRAS inhibitor with activity against several KRAS mutants both in active (ON) and inactive (OFF) forms.
During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several presentations highlighted novel strategies that move beyond traditional antibody-drug conjugate (ADC) payloads and targets.
Stem cells are a promising therapeutic modality to fight aging and age-related disease, speakers at the Bio-Plus Interphex Korea 2025 said. Progress in cell-based longevity medicine is being made, they added, although safety, ethical and regulatory issues are ongoing challenges.
Hirsutism is the excessive hair growth in women in male-typical areas, usually associated with androgen excess and other conditions such as polycystic ovary syndrome (PCOS). The genetic basis of hirsutism remains poorly understood; researchers from the University of Oulu and collaborators performed a meta-analysis of genome-wide association studies from 4,834 cases of hirsutism and 352,966 controls across three cohorts.
RSS
